The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Carestream Health Inc. accused Caliper Life Sciences Inc. of violating one of its patents, nearly five months after Caliper slapped Carestream with a patent infringement lawsuit of its own.
Hopkinton, Mass.-based lab equipment and services provider Caliper Life Sciences Inc. (NSDQ:CALP) sold a pair of of its product lines to Biotage AB.
The Swedish company acquired Caliper’s RapidTrace and TurboVap lines for $16.5 million in cash and the assumption of $500,000 in debt. The companies expect the deal to close by May 28.
Biotage said it hopes to bring up to eight Caliper employees who worked with the product lines into its workforce.
Caliper Life Sciences Inc. (NSDQ:CALP) slashed its net losses by two-thirds despite posting flat sales for the second quarter.
The Hopkinton, Mass.-based laboratory instruments and services provider reported sales of $28.7 million for the three months ended March 31, up 0.6 percent compared with $28.5 million during the same period last year.
Net losses for the quarter were $2.2 million, or 4 cents per share, down 66.6 percent compared with $6.7 million (14 cents per share) during Q1 2009.
Caliper Life Sciences, Inc. (Nasdaq: CALP) says that Shimazdu Scientific Instruments, Inc. has agreed to remove one of its DNA and RNA sequencers from the U.S. market after the company’s settled a 14-month patent dispute.
The Hopkinton, Mass.-based lab equipment and services provider had alleged that Shimazu’s MCE-202 MultiNA microchip electrophoresis system infringed on 11 different U.S. patents held by Caliper. The MultiNA is a microchip electrophoresis system the company says can quickly and easily perform DNA and RNA nucleic acid size confirmation and quantitation in life science research.
Caliper Life Sciences Inc. (NSDQ:CALP) made progress on the path to profitability during the fourth quarter, posting net income for the first time during 2009 and beating its previous revenue guidance by $1 million.
The Hopkinton, Mass.-based lab equipment and services provider posted revenues of $37.7 million during the three months ended Dec. 31, 2009, up 2.6 percent compared with $36.7 million during the same period in 2008. That’s about $1 million more than predicted; in January, the company said it expected to post $36.7 million in sale for the quarter.
Caliper Life Sciences Inc. (NSDQ:CALP) sued Carestream Health Inc., accusing the Rochester, N.Y.-based company of violating a suite of seven diagnostics imaging patents Caliper licenses from Stanford University.
The lawsuit, filed in the U.S. District Court for Eastern Texas, alleges that Carestream’s In-Vivo Molecular Imaging Solutions and Image Station Molecular Imaging Solutions lines, including a series of Kodak-brand devices Carestream acquired from Eastman Kodak Co. in 2007, infringes the patents covering Caliper subsidiary Xenogen Corp.’s IVIS imaging system. The IVIS devices are used for preclinical non-invasive imaging of mammals covered by the Caliper patents.
Caliper Life Sciences Inc. (NSDQ:CALP) formed a scientific advisory board of DNA sequencing experts and launched its first gene sequencing instrument, the LabChip XT.
The Hopkinton, Mass.-based lab instruments maker said it will work with the members of its new board to identify opportunities to improve sequencing workflows using its microfluidics technology.
A Minneapolis-area investment manager has been paring its stake in Caliper Life Sciences (NSDQ:CALP), selling into recent strength to pocket some year-end profits.
Caliper Life Sciences Inc. (NSDQ:CALP) said it expects to beat its own expectations for the fourth quarter’s top line, reporting preliminary revenues of $37.6 million for the three months ended Dec. 31, 2009.
The Hopkinton, Mass.-based lab equipment and services provider credited stronger-than-expected sales of its Ivis and LabChip instruments for the boon, along with license revenues from the deal it announced last week with Becton, Dickinson & Co. (NYSE:BDX). Caliper had predicted sales of between $33 million and $35 million for the quarter.
Caliper Life Sciences Inc. (NSDQ:CALP) settled its patent infringement beef with a recent Becton, Dickinson & Co. (NYSE:BDX) acquisition by striking a deal to license its microfluidics technology to BD.
The Hopkinton, Mass.-based lab equipment maker agreed to license the patent portfolio to Franklin Lakes, N.J.-based BD for an undisclosed amount, thereby settling a lawsuit filed by HandyLab Inc. in the U.S. District Court for Eastern Michigan.
